About
Overview
Company Leadership
Science
Technology Platform
Scientific Publications
Pipeline
Overview
CF101
CF102
CF602
Investor Information
Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Shareholders Meetings
Contact Us
Directions
Investor Information
Overview
News / Events
Press Releases
In The News
Research
Events Calendar
Presentations
Email Alerts
Company Information
Profile
Management
IR Contacts
FAQ
Financial Information
Quarterly & Annual Reports
Stock Information
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Section 16 Filings
Corporate Governance
Board of Directors
Governance Docs
Shareholders Meetings
Email Alerts
IR Contacts
RSS News Feed
Press Releases
All News
By Year:
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Jun 29, 2015 7:00 AM EDT
Can-Fite's CF602 Sexual Dysfunction Drug Backed by New Preclinical Data Progresses Towards an IND
Jun 19, 2015 7:00 AM EDT
Can-Fite Subsidiary OphthaliX Signs Definitive Agreement to Acquire Improved Vision Systems Ltd.
Jun 15, 2015 7:00 AM EDT
Can-Fite to Exhibit at Bio International Convention in Philadelphia on June 15 - 18, 2015
Jun 10, 2015 7:00 AM EDT
Can-Fite Granted Notice of Allowance for Patent Covering Manufacturing Process of CF101 in the U.S.
May 29, 2015 7:00 AM EDT
Can-Fite Reports First Quarter 2015 Results
May 11, 2015 7:00 AM EDT
Can-Fite's Phase II Liver Cancer Trial Approved in Europe
May 4, 2015 8:50 AM EDT
Can-Fite subsidiary, OphthaliX, Signs Term Sheet to Acquire Improved Vision Systems Ltd.
Apr 27, 2015 7:00 AM EDT
Can-Fite Reports Positive Results from Further Analysis of Phase II/III Psoriasis Trial
Apr 20, 2015 7:00 AM EDT
Can-Fite Applies for Orphan Drug Designation in Europe for CF102 in the Treatment of Liver Cancer
Mar 30, 2015 9:11 AM EDT
Can-Fite Reports Top-Line Results from Phase II/III Trial for CF101 in Treatment of Psoriasis
<< Previous
1...
17
18
19
20
21
22
23
24
25
26
...30
Next >>
Show All